MAP3K1 and central nervous system cancer: To provide more insight into the clinical significance of MAP3K1 expression in gliomas, we examined the MAP3K1 expression in glioma tissue from patients with varying survival outcomes, such as OS and disease‐free interval (DFI), using data from TCGA.